Apogee Therapeutics (APGE) investor relations material

Key presentations and data highlights

• Presented three abstracts at EADV, including a late breaker with new phase 2 data for an IL-13 antibody in atopic dermatitis (AD).

• Phase 2a data showed 66.9% EZ75 response and significant itch relief as early as one week, with only four dosing days.

• Safety profile aligned with existing therapies; conjunctivitis rates similar to Dupixent and no injection site reactions reported.

• Ongoing phase 2b study is testing three doses, with a mid-2026 readout planned.

• Maintenance study will report in the first half of next year, focusing on sustained response with quarterly or semiannual dosing.

Market landscape and competitive positioning

• Biologic market for AD is growing rapidly, with 25% overall growth and 48% increase in new-to-brand prescriptions year-over-year.

• Recent launches of Eblis and Nimluvio have outperformed previous benchmarks in their first year.

• Despite a crowded market, frontline therapy remains dominated by Dupixent, with new entrants mainly competing in later lines.

• Market research suggests strong physician interest in a new therapy with a quarterly dosing schedule and efficacy comparable or superior to current options.

Forward-looking statements and development plans

• Phase 2b and maintenance studies are progressing, with no safety concerns reported.

• Combination therapy approach is being pursued, with a head-to-head study ongoing and readout expected in the second half of next year.

• Company is prioritizing atopic dermatitis but also planning expansion into respiratory indications, starting with asthma.

• Strong cash position ($620M) provides runway into 2028, supporting late-stage development and expansion plans.

• Plans to launch the lead therapy as a monotherapy in AD by 2029, with additional expansion and combination data to be announced.